Skip to main content
SpringerLink
Log in

Future challenges

  • Chapter
  • First Online:
Handbook of Hepatitis C

Abstract

The recent development of very efficient antiviral drugs (Chap. 6) that can potentially cure virtually all treated patients, without clinically significant side effects, has opened new perspectives for the global management of hepatitis C.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mitruka K, Tsertsvadze T, Butsashvili M, et al. Launch of a Nationwide Hepatitis C Elimination Program–Georgia, April 2015. MMWR Morb Mortal Wkly Rep. 2015;64:753–757.

    Google Scholar 

  2. Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat. 2014;21 (Suppl 1):34–59.

    Google Scholar 

  3. Wedemeyer H, Duberg AS, Buti M, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21 (Suppl 1):60–89.

    Google Scholar 

  4. Tomaszewski KJ, Deniz B, Tomanovich P, Graham CS. Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy. Am J Public Health. 2012;102:e101–106.

    Google Scholar 

  5. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61 (RR-4):1–32.

    Google Scholar 

  6. Kohli A, Osinusi A, Sims Z, et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet. 2015;385:1107–1113.

    Google Scholar 

  7. Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012;4:115ra1.

    Google Scholar 

  8. Swadling L, Capone S, Antrobus RD, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med. 2014;6:261ra153.

    Google Scholar 

  9. Vanni E, Abate ML, Gentilcore E, et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology. 2009;50:697–706.

    Google Scholar 

  10. Milner KL, van der Poorten D, Trenell M, et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology. 2010;138:932–41 e1–3.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, USA

    Nicolas Goossens

  2. Department of Clinical Pathology, Faculty of Medicine, Geneva University Hospitals, Geneva, Geneve, Switzerland

    Sophie Clément

  3. Geneva University Hospitals, Geneva, Geneve, Switzerland

    Francesco Negro

Authors
  1. Nicolas Goossens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophie Clément
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Negro
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA

    Nicolas Goossens

  2. University Hospitals and Faculty of Medi, Clinical Pathology, Geneva, Geneve, Switzerland

    Sophie Clément

  3. Division of Gastroenterology and Hepatol, Geneva University Hospital, Geneva 14, Geneve, Switzerland

    Francesco Negro

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Goossens, N., Clément, S., Negro, F. (2016). Future challenges. In: Goossens, N., Clément, S., Negro, F. (eds) Handbook of Hepatitis C . Adis, Cham. https://doi.org/10.1007/978-3-319-28053-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-28053-0_7

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-28051-6

  • Online ISBN: 978-3-319-28053-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation